Emerging Trends and Opportunities in the Global Infectious Disease Treatment Market

Global Infectious Disease Treatment Market- Description
Infectious diseases are referred to as the type of ailments caused by the functions of certain microorganisms namely bacteria, virus, fungi, and parasites, among others. Most of these disorders are communicable in nature, i.e. they can be transferred from person to person through physical contact. The disease causing pathogens release toxic elements which in turn affects an individual. Some of the commonly known infectious diseases are influenza, herpes, syphilis, COVID-19, and Chlamydia, among others.

Global Infectious Disease Treatment Market- Overview
The global infectious disease treatment market is presently worth USD 113.5 billion and is poised to amplify at a CAGR of 7.96% over 2022-2030, thereby amassing USD 166.46 billion by end of the assessment timeframe.
The growing prevalence of communicable diseases and rising healthcare expenditure across various nations are primarily augmenting the outlook of this marketplace.

Furthermore, increasing health cognizance, surge in geriatric and infant population base, and technologies advancements in the medical sector are creating lucrative opportunities for the business vertical to prosper.
Also, booming biopharmaceutical sector, growing per capita income of the masses, and the importance of early diseases diagnosis and treatment are adding momentum to the progression of this marketplace.
Moreover, rising focus of drug manufacturers to develop innovative and effective treatments for infectious diseases is positively swaying the dynamics of this industry vertical.

On the contrary, dearth of skilled professionals in the field and rising instances of patent expiration pertaining to various drugs are hindering the remuneration scope of this market.

Global Infectious Disease Treatment Market- Key trends

Increasing geriatric and infant population base is aiding industry expansion

The world is witnessing a rapid surge in the elderly and infant population rate. It is evident that babies and aging people have a weaker immune system and hence are prone to various ailments. Disease causing parasites can easily attack infants and elderly individuals, thereby making them highly susceptible to a wide array of infectious diseases. This in turn is adding traction to the development of this business sphere.

Onset of the COVID-19 pandemic is accelerating market growth

The emergence of the coronavirus pandemic has paved a way for this marketplace to prosper. Being an infectious disease, it affected a large population base. The rising cases of COVID-19 infection pushed pharmaceutical industries and other related bodies to develop effective drugs and vaccines and provide potential cure against this deadly ailment. These factors in turn are augmenting the outlook of this market vertical.

Global Infectious Disease Treatment Market- Segmental assessment

By Mode of Treatment
• Drugs
• Vaccines

The drugs segment is poised to amass notable gains over the stipulated timeline owing to the booming biopharmaceutical sector across the globe.

By Target Organism
• Antibacterial
• Antifungal
• Antiviral
• Antiparasite
• Others

The antibacterial segment is anticipated to generate significant returns by 2030 due to the growing prevalence of ailments such as hepatitis, HIV, TB, and influenza, among others.

By Infection Type
• Bacterial
• Fungal
• Viral
• Parasitic
• Others

By Distribution Channels
• Hospitals
• Clinics
• Others

The hospitals segment is reckoned to grow considerably over the forecast duration ascribing to the rising number of hospitals across the globe.

Global Infectious Disease Treatment Market- Geographical landscape
The major regions constituting the geographical gamut of this industry vertical are North America, Middle East & Africa, Europe, Asia Pacific, and Latin America. Among these, North America is projected to capture a substantial revenue share over the forecast period of 2022-2030. This is attributable to the rising prevalence of infectious diseases, growing geriatric and infant population base, along with increasing healthcare expenditure in the region.

Global Infectious Disease Treatment Market- Competitive hierarchy
The prime players definining the competitive terrain of this market vertical are Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), bioMérieux SA (France), Becton, Dickinson and Company (US), PerkinElmer, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Grifols S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), Ortho Clinical Diagnostics Holdings plc (US), Quidel Corporation (US), Meridian Bioscience (US), Genetic Signatures Ltd. (Australia), OraSure Technologies (US), Trinity Biotech Plc. (Ireland), Epitope Diagnostics (US), Chembio Diagnostic Systems (US), Seegene, Inc. (South Korea), Co-Diagnostics (US), ELITechGroup (France), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International (US), Vela Diagnostics (Singapore) and Uniogen Oy (Finland).
Notably, in February 2021, Thermo Fisher Scientific announced the acquisition of Mesa Biotech to enhance its offerings in the field.

Report scope
Global Infectious Disease Treatment Market: Historical Years- 2018-2021
Global Infectious Disease Treatment Market: Forecast Period- 2022-2030
Global Infectious Disease Treatment Market 2022- USD 113.5 billion
Global Infectious Disease Treatment Market CAGR- 7.96%
Global Infectious Disease Treatment Market- USD 166.46 billion

Key segments reported-
• By Mode of Treatment (Drugs and Vaccines)
• By Target Organism (Antibacterial, Antifungal, Antiviral, Antiparasite, and Others)
• By Infection Type (Bacterial, Fungal, Viral, Parasitic, and Others)
• By Distribution Channels (Hospitals, Clinics, and Others)

Major regions and countries covered-
• North America (U.S., Canada, and Mexico)
• Latin America (Brazil, Argentina, and Colombia)
• Europe (Germany, U.K., France, Italy, Spain, and Russia)
• Middle East & Africa (UAE, Saudi Arabia, Egypt, and South Africa)
• Asia Pacific (China, Japan, India, Australia, South Korea, and ASEAN)

Top players profiled- Thermo Fisher Scientific Inc. (US), Abbott Laboratories (US), F. Hoffmann-La Roche Ltd. (Switzerland), Siemens Healthineers AG (Germany), Danaher Corporation (US), bioMérieux SA (France), Becton, Dickinson and Company (US), PerkinElmer, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Grifols S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), Ortho Clinical Diagnostics Holdings plc (US), Quidel Corporation (US), Meridian Bioscience (US), Genetic Signatures Ltd. (Australia), OraSure Technologies (US), Trinity Biotech Plc. (Ireland), Epitope Diagnostics (US), Chembio Diagnostic Systems (US), Seegene, Inc. (South Korea), Co-Diagnostics (US), ELITechGroup (France), Trivitron Healthcare (India), Meril Life Sciences Pvt. Ltd. (India), InBios International (US), Vela Diagnostics (Singapore) and Uniogen Oy (Finland).”